Literature DB >> 11869388

Healthcare costs of intellectual disability in the Netherlands: a cost-of-illness perspective.

J J Polder1, W J Meerding, L Bonneux, P J van der Maas.   

Abstract

Healthcare costs are continuously increasing, and impose a strong responsibility on governments for an adequate allocation of resources among healthcare provisions and patients. The aims of the present study were to describe the healthcare costs of intellectual disability (ID) and other mental disorders in the context of the total costs of all other diseases, and to determinate the future need of healthcare resources, especially for ID and mental disorders. The present authors performed a top-down cost-of-illness study comprising all healthcare costs of the Netherlands in 1994. Data on healthcare use were obtained for all 22 healthcare sectors, and used to ascribe costs to disease groups, age and sex. Costs of mental disorders are by far the largest in the Dutch healthcare system. Some 25.8% of total disease-specific costs could be ascribed to mental disorders: psychiatric conditions, 10.6%; ID, 9.0%; and dementia, 6.2%. There are large differences between age and sex groups. The costs of ID and schizophrenia are higher among men, and the costs of dementia and depression are higher among women. The age pattern shows two peaks: the first occurs at 25-35 years of age (ID and psychiatric conditions); and the second at 75-85 years of age (dementia). Time trends between 1988 and 1994 show an average annual growth rate of 5.2% for total healthcare costs: psychiatric conditions, 4.8%; ID, 5.4%; and dementia, 9.4%. Demographic projections suggest a less-than-average cost increase for ID and psychiatric disorders (with annual growth rates of 0.2% and 0.4%, respectively) compared to the costs of dementia and total healthcare (with annual growth rates of 1.6% and 0.9%, respectively). Intellectual disability and mental disorders represent a large part of healthcare use in the Netherlands. The costs will inevitably increase because of the ageing of the population and increasing life expectancy among people with disabilities. Non-specific cost containment measures may endanger the quality of care for vulnerable people at younger and older ages.

Entities:  

Mesh:

Year:  2002        PMID: 11869388     DOI: 10.1046/j.1365-2788.2002.00384.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  10 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Consensus guidelines for primary health care of adults with developmental disabilities.

Authors:  William F Sullivan; John Heng; Donna Cameron; Yona Lunsky; Tom Cheetham; Brian Hennen; Elspeth A Bradley; Joseph M Berg; Marika Korossy; Cynthia Forster-Gibson; Maria Gitta; Chrissoula Stavrakaki; Bruce McCreary; Irene Swift
Journal:  Can Fam Physician       Date:  2006-11       Impact factor: 3.275

3.  Novel HIVEP2 Variants in Patients with Intellectual Disability.

Authors:  Joohyun Park; Roberto Colombo; Karin Schäferhoff; Luigi Janiri; Mona Grimmel; Marc Sturm; Ute Grasshoff; Andreas Dufke; Tobias B Haack; Martin Kehrer
Journal:  Mol Syndromol       Date:  2019-04-03

4.  Intellectual developmental disorders: towards a new name, definition and framework for "mental retardation/intellectual disability" in ICD-11.

Authors:  Luis Salvador-Carulla; Geoffrey M Reed; Leila M Vaez-Azizi; Sally-Ann Cooper; Rafael Martinez-Leal; Marco Bertelli; Colleen Adnams; Sherva Cooray; Shoumitro Deb; Leyla Akoury-Dirani; Satish Chandra Girimaji; Gregorio Katz; Henry Kwok; Ruth Luckasson; Rune Simeonsson; Carolyn Walsh; Kemir Munir; Shekhar Saxena
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

5.  The size, burden and cost of disorders of the brain in the UK.

Authors:  Naomi A Fineberg; Peter M Haddad; Lewis Carpenter; Brenda Gannon; Rachel Sharpe; Allan H Young; Eileen Joyce; James Rowe; David Wellsted; David J Nutt; Barbara J Sahakian
Journal:  J Psychopharmacol       Date:  2013-07-24       Impact factor: 4.153

6.  Psychiatric care utilization among older people with intellectual disability in comparison with the general population: a register study.

Authors:  A Axmon; P Björne; L Nylander; G Ahlström
Journal:  BMC Psychiatry       Date:  2016-11-09       Impact factor: 3.630

7.  Developing and feasibility testing of data collection methods for an economic evaluation of a supported selfmanagement programme for adults with a learning disability and type 2 diabetes.

Authors:  John L O'Dwyer; Amy M Russell; Louise D Bryant; Rebecca E A Walwyn; Alexandra M Wright-Hughes; Elizabeth H Graham; Judy M Wright; Shaista Meer; Jacqueline Birtwistle; Amanda J Farrin; Allan O House; Claire T Hulme
Journal:  Pilot Feasibility Stud       Date:  2018-04-23

8.  Correlates of Sedentary Behaviour in Adults with Intellectual Disabilities-A Systematic Review.

Authors:  Alyt Oppewal; Thessa I M Hilgenkamp; Liselotte Schäfer Elinder; Ellen Freiberger; Pauli Rintala; Myriam Guerra-Balic; Maria Giné-Garriga; Antonio Cuesta-Vargas; Guillermo R Oviedo; Oriol Sansano-Nadal; Rocio Izquierdo-Gómez; Ingi Einarsson; Antti Teittinen; Craig A Melville
Journal:  Int J Environ Res Public Health       Date:  2018-10-17       Impact factor: 3.390

9.  Etiology of intellectual disability in individuals from special education schools in the south of Brazil.

Authors:  Luan Freitas Oliveira; Tiago Fernando Chaves; Nathacha Baretto; Gisele Rozone de Luca; Ingrid Tremel Barbato; Jorge Humberto Barbato Filho; Maristela Ocampos; Angelica Francesca Maris
Journal:  BMC Pediatr       Date:  2020-11-04       Impact factor: 2.125

10.  A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation.

Authors:  Patrick S Tarpey; Raffaella Smith; Erin Pleasance; Annabel Whibley; Sarah Edkins; Claire Hardy; Sarah O'Meara; Calli Latimer; Ed Dicks; Andrew Menzies; Phil Stephens; Matt Blow; Chris Greenman; Yali Xue; Chris Tyler-Smith; Deborah Thompson; Kristian Gray; Jenny Andrews; Syd Barthorpe; Gemma Buck; Jennifer Cole; Rebecca Dunmore; David Jones; Mark Maddison; Tatiana Mironenko; Rachel Turner; Kelly Turrell; Jennifer Varian; Sofie West; Sara Widaa; Paul Wray; Jon Teague; Adam Butler; Andrew Jenkinson; Mingming Jia; David Richardson; Rebecca Shepherd; Richard Wooster; M Isabel Tejada; Francisco Martinez; Gemma Carvill; Rene Goliath; Arjan P M de Brouwer; Hans van Bokhoven; Hilde Van Esch; Jamel Chelly; Martine Raynaud; Hans-Hilger Ropers; Fatima E Abidi; Anand K Srivastava; James Cox; Ying Luo; Uma Mallya; Jenny Moon; Josef Parnau; Shehla Mohammed; John L Tolmie; Cheryl Shoubridge; Mark Corbett; Alison Gardner; Eric Haan; Sinitdhorn Rujirabanjerd; Marie Shaw; Lucianne Vandeleur; Tod Fullston; Douglas F Easton; Jackie Boyle; Michael Partington; Anna Hackett; Michael Field; Cindy Skinner; Roger E Stevenson; Martin Bobrow; Gillian Turner; Charles E Schwartz; Jozef Gecz; F Lucy Raymond; P Andrew Futreal; Michael R Stratton
Journal:  Nat Genet       Date:  2009-04-19       Impact factor: 38.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.